Navigation Links
MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition
Date:10/16/2009

WASHINGTON, October 16, 2009 MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2009 National Conference & Exhibition that add to the company's growing body of research on the burden of respiratory syncytial virus (RSV) on children, as well as pediatric infectious disease prevention.

"With influenza and RSV becoming more widespread this time of year, it remains important to better understand the impact of infectious diseases on pediatric health and the healthcare system, as well as what we can do to prevent illness," said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. "The data being presented at the conference build on our extensive foundation of research and help advance innovative solutions for preventing illnesses that negatively impact the health of children."

MedImmune abstracts to be presented at AAP on RSV include:

  • "Late Breaking Trial: A Randomized Controlled Trial of RSV Prophylaxis with Motavizumab vs Palivizumab in Young Children with Hemodynamically Significant Congenital Heart Disease."
    Feltes, T. et al., Oral Presentation; 9:30 AM - Oct 18, 2009; H2019 Section on Cardiology & Cardiac Surgery Program Washington Convention Center, Room 201

    BACKGROUND: Congenital heart disease (CHD) patients are at high risk of complications from RSV lower respiratory infection and may benefit from passive immunoprophylaxis. Motavizumab is an investigational RSV-specific monoclonal antibody that is currently being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This randomized, double-blind, active-controlled clinical trial evaluated the safety and tolerability of motavizumab in children with congenital heart disease a population at high risk for serious RSV disease. Secondary objectives sought to determine the effect of motavizumab on rates of RSV-related hospitalization and RSV-specific lower respiratory tract infections, as well as describe motavizumab's pharmacokinetics and immune response.

  • "Serious Early Childhood Wheezing Following Respiratory Syncytial Virus Lower Respiratory Tract Infection During Infancy Among Preterm Infants"
    Romero, JR et al (presenter: Hasan Jafri, MD)[(Friday, October 16, 2009; Room 145 (Washington Convention Center)]

    BACKGROUND: Prior studies have suggested that RSV infection is associated with the development of recurrent wheezing in early childhood. However, these studies have had limited sample sizes and lacked laboratory confirmation. This retrospective cohort study sought to determine the relationship between medically attended RSV and recurrent wheezing in the third year of life. Charts of nearly 90,000 infants born at 32 weeks gestation or greater were analyzed for evidence of recurring wheezing and RSV infection, and laboratory testing for RSV was confirmed.

  • "Increased Medical Costs and Use within a Year After Respiratory Syncytial Virus Lower Respiratory Tract Infection Among Commercially-Insured Late-Preterm Infants"
    Palmer, L et al (presenter: Lisa Palmer, MD) [Friday, October 16, 2009; Room 145 (Washington Convention Center)]

    BACKGROUND: RSV is the leading cause of hospitalization for infants up to the age of one, and is responsible for one of every 13 visits to a pediatrician and one of every 38 emergency room trips for children up to the age of five. This burden on the healthcare system has associated costs. This retrospective cohort study evaluated the total healthcare costs and use of services from infants born between 33 36 weeks gestation infected with RSV lower respiratory tract infection (LRI). These late-preterm infants were compared with a control group of infants without RSV LRI, all of whom were commercially insured.

MedImmune abstracts to be presented at AAP on influenza include:

  • Survey of Physician-Led Influenza Immunization Programs in Schools
    Harry F. Hull, M.D., HF Hull & Associates, Oral Presentation: October 19; 11:45-11:55 AM Session: Council on School Health

    BACKGROUND: The American Academy of Pediatrics, American Academy of Family Physicians, and the Advisory Committee on Immunization Practices now recommend annual influenza immunizations for all children aged six months to 18 years. School-located immunization programs (SIPs) may offer an efficient, less costly means to reach large numbers of school-aged children. There have been reports of physician-led SIPs conducted independently from public health departments, but little is known about these programs. This study documented the experience of physician-led SIPs for the benefit of other physicians considering organizing SIPs.


'/>"/>

Contact: Tor Constantino
constantinos@MedImmune.com
301-398-5801
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza
2. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
3. MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
4. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
5. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
6. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
7. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
8. MedImmune Expands Scientific and Engineering Leadership
9. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
10. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
11. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: